ClinicalTrials.gg
RecruitingNCT06542822IRONHEARTUpdated Aug 7, 2024

IRONHEART: Intravenous Iron in Non-ischaemic Heart Failure

An observational study in Heart Failure and Iron Deficiencies, sponsored by University Hospital Southampton NHS Foundation Trust. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-07.

Sponsored by University Hospital Southampton NHS Foundation Trust · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2026, 9 months ago, but the record still lists the study as recruiting.
  • Started Apr 2024; still recruiting 2 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
16
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 482 studies in Heart Failure with a site in United Kingdom — 100 open to participants now, 127 under way, 18 of them phase 3. Heart Failure · United Kingdom.

Planned enrollment
158th of 166
16 · median 281
Started
2024
with 36 others
Observational
166 of 482
46 open now
Primary completion
2026-02
later than 27 of 126 live
Registered
431st of 482
by date

Among the 482 studies in Heart Failure with a site in United Kingdom, this one is the 158th largest by planned enrollment of the 166 observational ones that give a count, is one of 37 that started in 2024, is one of 166 observational ones, reaches primary completion later than 27 of the 126 other live ones, and was the 431st registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

100 of the 482 studies in Heart Failure with a site in United Kingdom are open now. Recruiting first, the newest first:

95 more — sign in →

All 100 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 482 studies in Heart Failure with a site in United Kingdom, or all of them as a file.
02

Study summary

The aim of this study is to observe the effect of intravenous ferric derisomaltose in participants with non-ischaemic heart failure (LVEF\<40%), iron deficiency (TSATS\<20%) and established on heart failure therapy including Sodium-glucose cotransporter 2 inhibitors (SGLT2i). Participants will undergo baseline laboratory blood tests, cardiac magnetic resonance imaging (cMRI), six-minute walk test, musculoskeletal function test and Kansas City Cardiomyopathy Questionnaire (KCCQ). These investigations will be repeated at 24 hours and 30 days after the administration of intravenous ferric derisomaltose.

Read the detailed description

Heart failure is a neuro-endocrine syndrome in which patients report symptoms of breathlessness and lethargy accompanied with signs of fluid overload.

Iron deficiency is very common in heart failure, affecting up to 50% of patients. Its presence in this population is associated with worsening symptoms and increased risk of death. Human clinical trials have shown that administering intravenous iron improves quality of life and exercise tolerance. The European Society Guidelines gives a 1A class recommendation for intravenous iron replacement in symptomatic heart failure patients.

Iron is an essential micro-nutrient required in mitochondrial metabolism, handling of reactive oxygen species and cellular metabolism. Heart failure leads to a pro inflammatory state, resulting in reduced gastrointestinal absorption, and inhibition of iron mobilisation. Mouse models have shown reversal of cardiac fibrosis, cardiac remodelling, and reduction in the pro inflammatory state when treated with intravenous iron. Similarly iron deficient human cardiomyocytes show adverse remodelling and altered function reversed with iron repletion.

The investigators aim to recruit 16 participants with non-ischaemic heart failure, established on optimal medical therapy, including SGLT2i therapy, for four weeks prior to the start of the trial. Initial baseline investigations will include: cMRI, six-minute walk test, hand grip strength test, laboratory blood tests and a KCCQ-12. Intravenous ferric derisomaltose will be given as standard of care. These investigations will be repeated at 24 hours and at 30 days after the administration of intravenous ferric derisomaltose.

The study aims to observe changes pre and post administration of intravenous derisomaltose in the following:

  • Changes in cardiac function and parametric measurements (T1/T2) as assessed by cardiac magnetic resonance imaging.
  • Changes in high sensitivity troponin, N Terminal pro-Brain Natriuretic Peptide (NT pro-BNP) and serum phosphate levels.
  • Changes in the submaximal exercise test (six-minute walk) and musculoskeletal function test (hand grip test).
  • Changes in heart failure symptoms as assessed by KCCQ Questionnaire.
03

Conditions studied

  • Heart Failure
  • Iron Deficiencies

Keywords

  • Ferric derisomaltose
  • Non-ischaemic heart failure
  • Chronic heart failure
  • Iron deficiency
  • Left ventricular failure
  • Iron homeostasis
  • Cardiac MRI
  • Cardiac Magnetic resonance imaging
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Participants with non-ischaemic cardiomyopathy with a left ventricular function less than 40% and iron deficient as per the following criteria: Transferrin saturations \< 20%

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants capable of giving .
  • Aged 18yrs and above.
  • Diagnosed with heart failure and a reduction of their \< 40% by any modality.
  • Non ischaemic cardiomyopathy as determined by baseline cardiac magnetic resonance imaging.
  • Iron deficient per this definition: Transferrin saturations \< 20%.
  • Established on Heart failure therapy including SGLT2i therapy for a minimum of four weeks prior to recruitment.
  • score of I - III class.

Exclusion criteria

Exclusion Criteria:

  • classification Score >IV
  • Ischaemic cardiomyopathy
  • Chronic kidney stage: Estimated (eGFR) \< 30
  • Requirement for renal dialysis
  • Atrial fibrillation / atrial flutter
  • Non cardiac and cardiac palliative diagnosis
  • Active cancer diagnosis
  • Moderate to severe valvular heart disease
  • Cardiac electronic implantable device: Cardiac resynchronization therapy, Implantable cardioverter-defibrillator, left ventricular assist device
  • Cardiac \& non cardiac transplant participants
  • Myocardial infarction, Percutaneous Coronary Intervention, Coronary Artery Bypass Graft surgery in the last 30 days
  • Complex congenital heart disease
  • Pregnancy
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
16 participants (estimated)
Patient registry
No

Groups and cohorts

  • IRONHEART Observational Study Group

    16 participants, with non-ischaemic heart failure, with iron deficiency TSATS \<20% and heart failure with a reduced ejection fraction \<40%. Cohort will have to be established on guideline directed heart failure therapy. Participants meeting eligibility criteria will undergo baseline quality of life questionnaires, hand grip tests and six minute walk tests before receiving intravenous iron derisomaltose and repeating these investigations again after 24 hours and 30 days including a cardiac magnetic resonance imaging.

    Drug: Ferric derisomaltose

Interventions

06

What researchers measure

Primary outcomes

  1. Ejection Fraction quantified on Cardiac Magnetic Resonance Imaging

    Changes in Ejection Fraction quoted in (%)

    Time frame: 24 Hours and 30 days

Secondary outcomes

  1. T1 Mapping quantified on Cardiac Magnetic Resonance Imaging

    Changes in T1 Parametric Mapping quantified in (msec)

    Time frame: 24 Hours and 30 days

  2. T2 Mapping quantified on Cardiac Magnetic Resonance Imaging

    Changes in T2 Parametric Mapping quantified in (msec)

    Time frame: 24 Hours and 30 Days

  3. Extracellular Volume (ECV) Fraction quantified on Cardiac Magnetic Resonance Imaging

    Changes in ECV Fraction quoted in (%)

    Time frame: 24 Hours and 30 Days

  4. Ventricular Volumes quantified on Cardiac Magnetic Resonance Imaging

    Changes in left and right ventricular volumes quantified in (ml)

    Time frame: 24 Hours and 30 Days

  5. Indexed Ventricular Volume quantified on Cardiac Magnetic Resonance Imaging

    Changes in indexed left and right ventricular volumes. Weight and Height will be combined to calculate Body Surface Area (m2). Left Ventricular Volume in (ml) will be divided by Body Surface Area to give indexed value (ml/m2)

    Time frame: 24 Hours and 30 Days

  6. Strain analysis as quantified on Cardiac Magnetic Resonance Imaging

    Changes in strain as assessed by feature tracking on cardiac magnetic resonance imaging

    Time frame: 24 Hours and 30 Days

  7. Quality of Life assessment: KCCQ-12 questionnaire

    Changes in Kansas City Cardiomyopathy Questionnaire. Four sub-domains: Physical limitation, Symptom Frequency, Quality of life and social limitations. Scores range from 0 - 100, with higher scores reflecting a better heart status.

    Time frame: 24 Hours and 30 Days

  8. Submaximal Exercise Test: Six Minute Walk Test

    Changes in distance walked (meters) in six minutes

    Time frame: 24 Hours and 30 Days

  9. Musculoskeletal function test: Hand grip test

    Changes in Isometric Grip Force in (KG)

    Time frame: 24 Hours and 30 Days

  10. Haemoglobin

    Laboratory Blood Test

    Time frame: 30 Days

  11. High Sensitivity troponin

    Laboratory Blood Test

    Time frame: 24 Hours and 30 Days

  12. Phosphate

    Laboratory Blood Test

    Time frame: 24 Hours and 30 Days

  13. N-terminal pro B type natriuretic peptide (NTproBNP)

    Laboratory Blood Test

    Time frame: 30 Days

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for Feb 2026, 22 months after the start.

Of 799 non-industry observational studies under Heart Failure, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 100. This study's planned 22 months is below that.

Counting every sponsor, half of 982 studies reached it within 41 months; a quarter within 23 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2024
First posted
Aug 7, 2024
StartActual
Apr 15, 2024
Primary completionEst.
Feb 2026
CompletionEst.
Feb 2027
Last update
Aug 7, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06542822
Collaborators
Portsmouth Hospitals NHS Trust
Responsible party
Sponsor
First posted
Aug 7, 2024
Start date
Apr 15, 2024
Primary completion
Feb 2026 (estimated)
Completion
Feb 2027 (estimated)
Last update
Aug 7, 2024

Study contacts

Flett
Contact
andrew.flett@uhs.nhs.uk
+442381205906
Rachael Pulham
Contact
sponsor@uhs.nhs.uk
+442381205044
Andrew S Flett, MBBS BSc MD
principal investigator · University Hospital Southampton NHS Foundation Trust

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion